MaxCyte (NASDAQ:MXCT) Downgraded by Wall Street Zen to Sell

Key Points

• MaxCyte has been downgraded from a "hold" rating to a "sell" rating by Wall Street Zen, indicating a more negative outlook for the stock.
• The company reported a loss of $0.12 EPS for the last quarter, missing the consensus estimate, which reflects ongoing financial challenges.
• MaxCyte's stock has a current market cap of $147.12 million with a consensus target price of $7.00 despite recent downgrades and mixed analyst ratings.

Wall Street Zen downgraded shares of MaxCyte (NASDAQ:MXCT - Free Report) from a hold rating to a sell rating in a research report report published on Saturday morning.

MXCT has been the topic of a number of other reports. William Blair cut shares of MaxCyte from an "outperform" rating to a "market perform" rating in a research note on Thursday, August 7th. Stephens assumed coverage on shares of MaxCyte in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $6.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, MaxCyte currently has an average rating of "Hold" and an average price target of $7.00.

MaxCyte Stock Up 10.6%

Shares of MXCT traded up $0.14 during midday trading on Friday, reaching $1.41. 1,100,475 shares of the stock were exchanged, compared to its average volume of 757,247. MaxCyte has a twelve month low of $1.26 and a twelve month high of $5.20. The company has a market cap of $149.79 million, a P/E ratio of -3.27 and a beta of 1.23. The stock's 50 day simple moving average is $2.12 and its 200 day simple moving average is $2.76.

MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.02). The firm had revenue of $8.51 million for the quarter, compared to analyst estimates of $9.57 million. MaxCyte had a negative return on equity of 22.12% and a negative net margin of 125.22%. As a group, analysts predict that MaxCyte will post -0.42 earnings per share for the current year.

Hedge Funds Weigh In On MaxCyte

Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in MaxCyte by 123.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock valued at $31,000 after buying an additional 4,173 shares during the period. Farther Finance Advisors LLC lifted its stake in MaxCyte by 7,935.4% in the second quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company's stock valued at $26,000 after buying an additional 11,665 shares during the period. Prudential Financial Inc. acquired a new position in MaxCyte in the second quarter valued at approximately $26,000. CWM LLC lifted its stake in MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company's stock valued at $26,000 after buying an additional 5,836 shares during the period. Finally, May Hill Capital LLC bought a new stake in shares of MaxCyte during the second quarter valued at approximately $27,000. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.